HRSA - Health Resources and Service Administration U.S. Department of Health & Human Services
Home
Questions
Order Publications
 
Grants Find Help Service Delivery Data Health System Concerns About HRSA
The HIV/AIDS Program: HAB Performance Measures / Scope of HAB Core Clinical PM
 

< Previous | Home | Next >

Scope of HAB Core Clinical Performance Measures
  1. Are the core clinical performance measures suitable to all Parts?
  2. Are the December 2007 performance measures different from the ones released in April 2007?
  3. Does this mean that HAB considers these five (5) measures the really important ones?
  4. Why aren't general health indicators included in the HAB core performance measures?
  5. Why aren't performance measures for case management or other supportive services included in the HAB core performance measures?
  6. What is the difference between a performance measure and standard of care?
 
1. Are the core clinical performance measures applicable to all Parts?  TOP

Yes, the HAB PMs can be used by all programs funded by the Ryan White HIV/AIDS Program. The measures can be used either at the provider or system level. The measures can be rolled up to look at issues from a system perspective, such as with Part A and B Programs. Programs can also work with their subcontractors, vendors or subgrantees to implement the performance measures at the provider level. Grantees are encouraged to include the core clinical performance measures in their quality management plan.

 
2. Are the December 2007 performance measures different from the ones released in April 2007?  TOP

Yes. In April 2007, a set of draft performance measures were released for public comment. Based on the tremendous feedback received, the performance measures were revised to address many of the issues raised. The modified performance measures are being released in stages. The measures included in Group 1 represent the five (5) performance measures that are deemed critical for HIV programs to monitor. Additional clinical performance measures will be released in early 2008.

 
3. Does this mean that HAB considers these five (5) measures the really important ones?  TOP

HAB considers all of the clinical performance measures that were released in April 2007 critical to good care. The measures are being released in phases to allow for staged implementation. If a clinical program has no performance measures, these five measures provide an excellent start and can serve as a foundation on which to build.

 
4. Why aren't general health indicators included in the HAB core performance measures?  TOP

National performance measures have been established for a wide range of general health conditions, such as immunizations, prenatal care and screenings. Since there are currently no national consensus performance measures for HIV care, the HAB HIV Core Clinical Performance Measures focus on key elements of care that are unique to the HIV-infected patient population served by the Ryan White HIV/AIDS Programs.

 
5. Why aren't performance measures for case management or other supportive services included in the HAB core clinical performance measures?  TOP

Because these measures focus on medical care, case management measures for case management and other supportive services have not been included. Separate performance measures are expected to be released in 2008 related to case management, oral health, AIDS Drug Assistance Program (ADAP) and systems.

 
6. What is the difference between a performance measure and standard of care?  TOP

A performance measure provides an indication of an organization's performance in relation to a specified process or outcome. Standards of care are guidelines that outline the expectations of care around a specific issue or topic and are created by a group of subject matter or clinical experts. Because performance measures and standards of care each serve a different purpose, they are not always in accordance. For instance, with the Medical Visit performance measure, the standard of care states that routine monitoring should occur at least every three to four months depending on the stage of disease. For the purpose of the performance measure, the time frame of six months was determined by clinical expert consensus to allow for those patients that are well controlled clinically and stable on their current regimen. Per the guidelines, patients can and should be seen at more frequent intervals as dictated by their current health status.